Literature DB >> 8509270

Monocyte chemotactic and phagocytic responses in migraine and tension-type headache patients.

V Gallai1, P Sarchielli, A Trequattrini, M Paciaroni.   

Abstract

Monocyte chemotactic and phagocytic responses were assessed in two groups of migraine patients (with and without aura) and in two groups of tension-type headache patients (episodic and chronic). The chemotactic but not the phagocytic response, assessed interictally, is significantly lower in migraine patients (p < 0.006) and in episodic tension-type headache patients, though not so significantly in the latter (p < 0.05), than in the control individuals. The chemotactic response tends to increase significantly during attack in migraine patients both with and without aura (p < 0.008 and p < 0.007 respectively). The same was evident for the phagocytic response in both migraine patient groups (p < 0.007 and 0.0004). No modifications of monocyte functions were found during attacks neither in episodic nor chronic tension-type headache patients. These findings suggest that one or more mediators of neurogenic inflammation having phagocytic and chemotactic enhancing properties (substance P, prostaglandin E and thromboxane A2 etc.) are implicated in the modification of monocyte function. The demonstration of a defect in monocyte function during the interictal period in migraine patients confirms the results of recent research which evidenced reduced capacity of monocyte to phagocyte and kill microorganisms in the course of migraine.

Entities:  

Mesh:

Year:  1993        PMID: 8509270     DOI: 10.1007/BF02335750

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  32 in total

1.  Plasma interleukin-1, tumour necrosis factor and hypothalamic-pituitary-adrenal axis responses during migraine attacks.

Authors:  J J van Hilten; M D Ferrari; J W Van der Meer; H J Gijsman; B J Looij
Journal:  Cephalalgia       Date:  1991-05       Impact factor: 6.292

2.  Substance P and astrocytes: stimulation of the cyclooxygenase pathway of arachidonic acid metabolism.

Authors:  H P Hartung; K Heininger; B Schäfer; K V Toyka
Journal:  FASEB J       Date:  1988-01       Impact factor: 5.191

3.  Lymphokine-activated killer (LAK) cell phenomenon in cluster headache. "In vitro" activation by recombinant interleukin-2.

Authors:  M Giacovazzo; G Stirparo; L DeStefano; P Martelletti; C Rinaldi-Garaci
Journal:  Headache       Date:  1989-03       Impact factor: 5.887

4.  Variations in the Leu7+ and LeuM3+ leukocyte subpopulations observed in cluster headache are dependent on HLA-DR antigens.

Authors:  M Giacovazzo; P Martelletti; M Valeri; A Piazza; P I Monaco; C U Casciani
Journal:  Headache       Date:  1987-01       Impact factor: 5.887

5.  Enhancement of phagocytosis - a newly found activity of substance P residing in its N-terminal tetrapeptide sequence.

Authors:  Z Bar-Shavit; R Goldman; Y Stabinsky; P Gottlieb; M Fridkin; V I Teichberg; S Blumberg
Journal:  Biochem Biophys Res Commun       Date:  1980-06-30       Impact factor: 3.575

Review 6.  Interactions between the neuroendocrine and immune systems: common hormones and receptors.

Authors:  D A Weigent; J E Blalock
Journal:  Immunol Rev       Date:  1987-12       Impact factor: 12.988

7.  Prostaglandin--E2 levels in the saliva of common migrainous women.

Authors:  J Vardi; S Flechter; A Alguati; I Regev; D Ayalon
Journal:  Headache       Date:  1983-03       Impact factor: 5.887

8.  Specific stimulation of human T lymphocytes by substance P.

Authors:  D G Payan; D R Brewster; E J Goetzl
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

Review 9.  Are TNF-alpha and IL-1 beta relevant in the pathogenesis of migraine without aura?

Authors:  V Covelli; I Munno; N M Pellegrino; M Altamura; P Decandia; C Marcuccio; A Di Venere; E Jirillo
Journal:  Acta Neurol (Napoli)       Date:  1991-04

10.  Increase in PGE2 and TXA2 in the saliva of common migraine patients. Action of calcium channel blockers.

Authors:  J O Tuca; J M Planas; P P Parellada
Journal:  Headache       Date:  1989-09       Impact factor: 5.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.